InnoCare Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

InnoCare Pharma Limited (HKG:9969) last week reported its latest half-year results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations. Revenues of CN¥1.1b fell slightly short of expectations, but earnings were a definite bright spot, with statutory per-share profits of CN¥0.14 an impressive 100% ahead of estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on InnoCare Pharma after the latest results.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Following the recent earnings report, the consensus from seven analysts covering InnoCare Pharma is for revenues of CN¥2.59b in 2026. This implies a noticeable 6.8% decline in revenue compared to the last 12 months. Statutory earnings per share are expected to nosedive 63% to CN¥0.20 in the same period. In the lead-up to this report, the analysts had been modelling revenues of CN¥2.31b and earnings per share (EPS) of CN¥0.11 in 2026. So we can see there's been a pretty clear increase in sentiment following the latest results, with both revenues and earnings per share receiving a decent lift in the latest estimates.

View our latest analysis for InnoCare Pharma

Despite these upgrades,the analysts have not made any major changes to their price target of HK$20.23, suggesting that the higher estimates are not likely to have a long term impact on what the stock is worth. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values InnoCare Pharma at HK$22.71 per share, while the most bearish prices it at HK$17.15. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await InnoCare Pharma shareholders.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that revenue is expected to reverse, with a forecast 13% annualised decline to the end of 2026. That is a notable change from historical growth of 28% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 22% annually for the foreseeable future. It's pretty clear that InnoCare Pharma's revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around InnoCare Pharma's earnings potential next year. They also upgraded their revenue estimates for next year, even though it is expected to grow slower than the wider industry. The consensus price target held steady at HK$20.23, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for InnoCare Pharma going out to 2028, and you can see them free on our platform here..

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for InnoCare Pharma (1 is significant) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.